Kaitlyn D’Onofrio

DocwireNews

During the second annual Houston Shock Symposium, Richard Smalling, MD, PhD, FACC, MSCAI, delivered the keynote address, during which he shared more than three decades&rsquo; worth of research regarding left ventricle (LV) unloading in acute ischemic shock.Dr. Smalling outlined several important questions to take into account when considering potential strategies for salvaging myocardium and improving outcomes in acute ischemic cardiogenic shock&mdash;as well as when designing trials to study these outcomes:<ul>
<li>How soon after the onset of myocardial ischemia must a beneficial intervention be initiated to reduce/prevent acute myocardial cell death?</li>
<li>What is/are the mechanisms of acute ischemic myocardial necrosis and what is the time frame relative to duration of ischemia and presence of reperfusion?</li>
<li>How can you measure acute myocardial salvage?</li>
<li>Can myocardial salvage still occur if a protective intervention is initiated relatively late (&gt;2 hours) after onset of ischemia?</li>
<li>What is/are the mechanisms of delayed ischemic myocardial necrosis?</li>
<li>How can you measure delayed myocardial salvage/reduced late myocardial necrosis?</li>
</ul>One crucial theme of research, treatment, and designing trials is timing. The importance of timing when making certain interventions was highlighted by a series of previous studies, which found good outcomes in animal models receiving early intervention. In an interview, Dr. Smalling said that one of the difficult parts of early intervention is that patients are not likely to present within the first two hours of symptoms.&ldquo;To get an early benefit you have to do the intervention within two hours of symptoms&mdash;which is hard to do in today&rsquo;s healthcare setting,&rdquo; he explained.During his keynote address, Dr. Smalling highlighted data from his 2011 trial, &ldquo;Intra-aortic Balloon Counterpulsation and Infarct Size in Patients With Acute Anterior Myocardial Infarction Without Shock: The CRISP AMI Randomized Trial,&rdquo; which was published in JAMA. The trial was designed to determine whether intra-aortic balloon counterpulsation (IABC) prior to reperfusion in ST-segment elevation myocardial infarction (STEMI) patients without shock could reduce myocardial infarct size.However, the researchers ran into a timing issue.&ldquo;We didn&rsquo;t know that you had to do the unloading way before three hours&rdquo; after onset of symptoms, which is when most patients arrived, Dr. Smalling said.&ldquo;You&rsquo;re not going to see a calcium overload benefit &hellip; [or] infarct size benefit, which is how we designed the trial.&rdquo; The trial, therefore, yielded a&nbsp; negative result.Still, in the few patients who received early intervention, the researchers saw successful myocardium salvage. After six months, there were three deaths in the IABC plus standard care group, and nine deaths in the standard care alone group (a tripling of the mortality rate), but the sample size was too small. One of the trial&rsquo;s secondary endpoints was time to death, shock, or new or worsening heart failure, which was significantly worse in the standard care group compared to the IABC group (21 events [12%] vs. 8 events [5%]). However, this was a secondary endpoint among a very small patient sample.Still, there were observable benefits.&ldquo;What we achieved was the inhibition of apoptosis with delayed unloading. And the effect was [&hellip;] across all timeframes.&rdquo; Therefore, even in patients who present six to eight hours after symptoms, unloading prior to reperfusion still had a positive effect.The most important takeaways, according to Dr. Smalling, went back to earlyintervention.&ldquo;You need to do LV unloading early,&rdquo; he concluded. &ldquo;We showed that you can have some benefit late, and the myocardial necrosis and heart failure can be prevented with later unloading.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Keynote Address: From Trial Design to Treatment, Timing is Key

Houston's Shock Symposium 2019

During the second annual Houston Shock Symposium, Richard Smalling, MD, PhD, FACC, MSCAI, delivered the keynote address, during which he shared more than three decades’ ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe